The software integration provides endocrinology practices that partner with SweetSpot the ability to seamlessly and regularly review data from patients using Eversense 365, the world’s first and only one-year CGM.
Senseonics won FDA clearance for the Eversense 365 one-year implantable CGM. With its global distribution partner, Ascensia Diabetes Care, it announced the launch for Eversense 365 on Oct. 1. The company also said earlier this month that it submitted the system for CE mark.
The sensor delivers consistent accuracy across one year, with almost zero false alerts from compression lows during the night. It offers the freedom to remove the transmitter device without wasting a sensor or adding a warm-up period. Eversense 365 also has on-body vibration alerts for improved discretion, alerting patients even when their mobile phone is out of sight.
SweetSpot, meanwhile, combines centralized software for managing diabetes with wrap-around clinical support services. Its integration with Eversense 365 means it can work alongside practices to act on this unique system’s CGM data in between patients’ scheduled appointments. Regular data reviews help ensure patients receive timely treatment adjustments, the companies say.
“We are pleased to enable integration with SweetSpot to help healthcare providers using the software platform to optimize care for patients using Eversense 365,” said Mukul Jain, Senseonics COO. “Our CGM offers a completely fresh approach to diabetes management by collecting a whole year of glucose data with just one CGM. We continue to focus on bringing Eversense 365 to more people across the country and are excited to see how integrations like this can further enhance our compelling offering for patients and healthcare providers.”
